Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa

INTRODUCTION: Andexanet alfa (AnXa) was developed for anticoagulant effect reversal of direct factor Xa inhibitors (DXaI) (apixaban, rivaroxaban, edoxaban) in emergency situations. Regular anti‐Xa assays are not suitable to evaluate anti‐Xa activity after AnXa administration because of the high samp...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourdin, Matthieu, Perrotin, Delphine, Mathieu, Olivier, Herve, Tristan, Depasse, François, Lu, Genmin, Conley, Pamela B., Contant, Geneviève
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453859/
https://www.ncbi.nlm.nih.gov/pubmed/34092030
http://dx.doi.org/10.1111/ijlh.13591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453859/
https://www.ncbi.nlm.nih.gov/pubmed/34092030
http://dx.doi.org/10.1111/ijlh.13591

Ejemplares similares